OPEN ACCESS Freely available online

ISSN: 2090-7214
Clinics in Mother and Child Health

Short Communication

Significance of Biomarkers to Progress Personalized Care in Cancer

Joseph Cushman*

Department of Medicine, Larner College of Medicine, University of Vermont, Vermont, USA

DESCRIPTION

Women's cancers, gynecology, and obstetrics are fields of medicine that are constantly evolving. With the advancement in technology, doctors are discovering new ways to diagnose and treat diseases and disorders specific to women. One such technology that has drastically improved diagnostic accuracy and treatment efficacy is the use of biomarkers. This article will explain what biomarkers are and how they can be used to detect and monitor women's cancers, gynecology, and obstetrics.

Biomarkers are molecules found in the body that can be used to measure certain processes or conditions. They can be used to detect disease, track its progression, and monitor its treatment. Examples of biomarkers include hormones, proteins, and genetic mutations. Biomarkers can be divided into two main categories: Diagnostic and prognostic. Diagnostic biomarkers are used to identify a particular condition or disease. They can also be used to determine the severity of a condition or disease. Prognostic biomarkers, on the other hand, are used to predict the likelihood of a particular outcome, such as the risk of recurrence or progression of a condition [1-4].

Biomarkers are powerful tools for helping to diagnose and treat various conditions in women's cancers. They are used to detect the presence of cancer cells in the body, as well as to monitor changes in the cells over time and this data is used to determine the necessary treatment. Biomarkers are also used to assess the risk of developing certain cancers, such as breast cancer. In addition, biomarkers can be used to detect the presence of recurrence or metastasis in cancer patients [5,6].

Biomarkers are also used in gynecology and obstetrics to assess the health of the reproductive system. They can be used to detect the presence of diseases such as endometriosis, as well as to monitor changes in hormones during the menstrual cycle, pregnancy, and menopause. Biomarkers are also used to assess the risk of developing certain conditions, such as preterm labor. In addition, biomarkers can be used to detect changes in the uterus during pregnancy, as well as to monitor the health of the mother and fetus [7-9].

Using biomarkers in women's cancers, gynecology, and obstetrics offers several benefits. They can help to detect diseases early, which can lead to more effective treatment. They can help to assess the risk of developing certain conditions. They can be used to monitor changes over time, which can help to inform treatment decisions. They can help to detect recurrence or metastasis in cancer patients. Biomarkers are an invaluable tool for diagnosing and treating women's cancers, gynecology, and obstetrics. As research continues, new and more accurate biomarkers are being developed, which will allow for more precise and effective diagnosis and treatment [10].

CONCLUSION

Biomarkers are an important tool for diagnosing and treating women's cancers, gynecology, and obstetrics. They can be used to detect the presence of cancer cells, as well as to monitor changes in the cells over time. They can also be used to assess the risk of developing certain conditions, such as preterm labor. As research continues, new and more accurate biomarkers are being developed, which will allow for more precise and effective diagnosis and treatment. In the future, biomarkers are expected to play an even bigger role in women's cancer, gynecology, and obstetrics. They will help to detect diseases earlier and more accurately, as well as to assess the risk of developing certain conditions.

REFERENCES

1. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288(8):980-987.
2. Chandler PD, Song Y, Lin J, Zhang S, Sesso HD, Mora S, et al. Lipid biomarkers and long-term risk of cancer in the Women's Health Study. Am J Clin Nutr. 2016;103(6):1397-1407.
3. Kooperberg C, Cushman M, Hsia J, Robinson JG, Aragaki AK, Lynch JK, et al. Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials. 2007;2(6):e28.

Correspondence to: Joseph Cushman, Department of Medicine, Larner College of Medicine, University of Vermont, Vermont, USA, E-mail: josephc@uvm.edu

Received: 28-Apr-2023, Manuscript No. CMCH-23-21727; **Editor assigned:** 01-May-2023, Pre QC No. CMCH-23-21727 (PQ); **Reviewed:** 15-May-2023, QC No. CMCH-23-21727; **Revised:** 22-May-2023, Manuscript No. CMCH-23-21727 (R); **Published:** 29-May-2023, DOI: 10.35248/2090-7214.23.S16.005

Citation: Cushman J (2023) Significance of Biomarkers to Progress Personalized Care in Cancer. Clinics Mother Child Health. S16:005.

4. Kaplan RC, McGinn AP, Baird AE, Hendrix SL, Kooperberg C, Lynch J, et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study. J Stroke Cerebrovasc Dis. 2008;17(6):344-355.
5. Cushman M, Larson JC, Rosendaal FR, Heckbert SR, Curb JD, Phillips LS, et al. Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative. Res Pract Thromb Haemost. 2018;2(2):e12100.
6. Beasley JM, Wertheim BC, LaCroix AZ, Prentice RL, Neuhouser ML, Tinker LF, et al. Biomarker-calibrated protein intake and physical function in the Women's Health Initiative. J Am Geriatr Soc. 2013;61(11):1863-1871.
7. Li J, Glenn AJ, Yang Q, Ding D, Zheng L, Bao W, et al. Dietary protein sources, mediating biomarkers, and incidence of type 2 diabetes: Findings from the Women's Health Initiative and the UK Biobank. Diabetes Care. 2022;45(8):1742-1753.
8. Tinker LF, Sarto GE, Howard BV, Huang Y, Neuhouser ML, Mossavar-Rahmani Y, et al. Biomarker-calibrated dietary energy and protein intake associations with diabetes risk among postmenopausal women from the Women's Health Initiative. Am J Clin Nutr. 2011;94(6):1600-1606.
9. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006;295(12):1412-1419.
10. Lee JD, Cai Q, Shu XO, Nechuta SJ. The role of biomarkers of oxidative stress in breast cancer risk and prognosis: a systematic review of the epidemiologic literature. J Womens Health (Larchmt). 2017;26(5):467-482.